Major trial aims to replace harsh transplants with targeted drugs for blood cancer
NCT ID NCT06860269
Summary
This large study aims to improve treatment for adults with acute lymphoblastic leukemia (ALL) by testing new targeted immunotherapy drugs. It will enroll 1,200 newly diagnosed patients to see if these drugs can control the cancer so well that a risky stem cell transplant is no longer needed for many people. The trial will also help doctors better decide which patients truly need a transplant.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Saint Louis
RECRUITINGParis, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.